Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
about
Fasting triglycerides as a predictor of incident diabetes, insulin resistance and β-cell function in a Canadian First Nation.Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo.Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study.Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapyAn assessment of molecular pathways of obesity susceptible to nutrient, toxicant and genetically induced epigenetic perturbation.The diabetogenic action of statins - mechanisms and clinical implications.Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Leucine-nicotinic acid synergy stimulates AMPK/Sirt1 signaling and regulates lipid metabolism and lifespan in Caenorhabditis elegans, and hyperlipidemia and atherosclerosis in mice.Association between cognitive vulnerability to depression - dysfunctional attitudes and glycaemic control among in-patients with type 2 diabetes in a hospital in Beijing: a multivariate regression analysis.Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million PatientsLeaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study
P2860
Q33604239-508C85CA-514A-47A7-9317-0A6C74614054Q33730894-F2D0B2E0-88F6-4887-822E-456896D3F929Q34898643-95E996D5-50E7-4386-96F0-0DFF79FE283DQ35875974-694E02CC-B5C2-40E5-8FAA-6DAF378F5AB5Q36730191-8180E154-73A3-44D6-A4E0-D2CA610AAFB0Q38669513-113C7296-9872-4BCD-B070-8A0B427553B2Q39312047-8F377A92-1EC1-4126-A04C-CA1FED8029F0Q39420208-5046E571-8494-4763-AF4C-54F06838902CQ41877399-B1CE2915-A4C7-4764-A3AE-899D814ACB3DQ47691822-A4B33FD7-4F68-486E-B15D-E63736889574Q48302242-0A9F6115-3DA6-4C84-95F5-ED94DC5CB97BQ58698213-CB6E4592-EC08-4C35-B6D1-B5614132B1CBQ58698291-BE40C9A3-CEC4-442A-8CC1-D68DCC12C8E7
P2860
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Lipid-lowering therapies, gluc ...... sms and clinical implications.
@en
type
label
Lipid-lowering therapies, gluc ...... sms and clinical implications.
@en
prefLabel
Lipid-lowering therapies, gluc ...... sms and clinical implications.
@en
P2860
P1476
Lipid-lowering therapies, gluc ...... isms and clinical implications
@en
P2093
Mohit Jain
P2860
P304
P356
10.1007/S10557-014-6534-9
P50
P577
2014-08-01T00:00:00Z